Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.37 |
| ▸ | FPR1 | P21462 | 3/20 | 0.36 |
| ▸ | FPR2 | P25090 | 3/20 | 0.36 |
| ▸ | CFD | P00746 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 7/20 | 0.34 |
| ▸ | MC3R | P41968 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | MC5R | P33032 | 2/20 | 0.33 |
| ▸ | MC1R | Q01726 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3045300 | 0.83 | KDM1A (0.41) | HTR2AHTR2CHTR2BDPP4 | |
| SCHEMBL3871554 | 0.78 | KDM1A (0.40) | — | |
| SCHEMBL15552976 | 0.76 | CFD (0.35) | CFD | |
| SCHEMBL15541196 | 0.74 | KDM1A (0.51) | HTR2AHTR2CHTR2BDPP4FPR1 | |
| SCHEMBL15554113 | 0.74 | SLC9A1 (0.42) | HTR2AHTR2CHTR2BDPP4 | |
| SCHEMBL2215854 | 0.72 | KDM1A (0.43) | KCNH2 | |
| Trifluoroacetic Acid SCHEMBL15540595 | 0.71 | KDM1A (0.54) | HTR2AHTR2CHTR2BDPP4KCNH2 | |
| SCHEMBL15212170 | 0.68 | KDM1A (0.45) | FPR1FPR2KCNH2 | |
| SCHEMBL16232155 | 0.67 | HTR2A (0.49) | HTR2AHTR2CHTR2BFPR1FPR2 | |
| SCHEMBL15541789 | 0.67 | HTR2A (0.49) | HTR2AHTR2CHTR2BMC4RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867226-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2018-11-14 | — | — | EP | disclosed |
| CN-105121429-B | Complement pathway modulators and uses thereof | 诺华股份有限公司 | 2017-12-12 | — | — | CN | disclosed |
| US-9815819-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| CN-105121429-A | Complement pathway modulators and uses thereof | NOVARTIS AG | 2015-12-02 | — | — | CN | disclosed |
| US-20150141455-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-21 | — | — | US | disclosed |
| EP-2867226-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | Novartis AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014002051-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141455-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | C5, C3AR1, C9 | HTR2A 1704/4885HTR2C 2131/4885HTR2B 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.